摘要
目的观察化疗产生的免疫抑制作用对三阴性乳腺癌（TNBC）治疗效果的影响。方法24只BABL/c裸鼠随机分为单纯荷瘤组、化疗组和联合组，每组8只。腋下接种MDAMB-231-HM细胞，构建TNBC小鼠荷瘤模型。单纯荷瘤组为空白组，化疗组腹腔注射5 mg/kg紫杉醇，联合组注射5 mg/kg紫杉醇和0.2 mg/kg胸腺肽，每周2次。3周后处死小鼠行肿瘤组织重量检测，脾脏细胞活性白细胞介素（IL）-2、肿瘤坏死因子-α（TNF-α）、IL-10和IL-6细胞因子酶联免疫吸附试验（ELISA）检测，血液单核细胞CD4＋/CD8＋流式细胞检测。结果（1）化疗组肿瘤瘤重[（1.32±0.67） g]显著低于荷瘤组[（3.12±0.32） g，P＝0.031]；联合组瘤重[（0.80±0.37） g]显著低于化疗组[（1.32±0.67） g，P＝0.037]。（2）化疗组脾脏细胞活性IL-2、IL-10和IL-6细胞因子水平较荷瘤组均显著降低，TNF-α水平降低但差异无统计学意义：48 h时IL-2水平：（13.39±1.21） ng/L比（16.65±1.28） ng/L（P＝0.030），36 h时IL-10水平：（223.03±32.24） ng/L比（267.98±42.12） ng/L（P＝0.041），36 h时IL-6水平：（39.03±10.24） ng/L比（47.98±12.12） ng/L（P＝0.025），36 h时TNF-α水平（26.94±2.94） ng/L比（29.45±3.45） ng/L。（3）胸腺肽免疫增强治疗能显著逆转化疗引起的IL-2、TNF-α和IL-10细胞因子水平下调，但对IL-6水平无逆转作用：48 h时IL-2水平：（19.96±1.05） ng/L比（13.39±1.21） ng/L（P＝0.003），36 h时TNF-α水平：（23.45±2.78） ng/L比（20.34±3.01） ng/L（P＝0.047），48 h时IL-10水平：（285.34±36.74） ng/L比（250.43±30.56） ng/L（P＝0.014），36 h时IL-6水平：（37.57±5.57） ng/L比（39.03±10.24） ng/L。（4）化疗组与荷瘤组比较CD4＋/CD8＋比值降低但差异无统计学意义（1.19±0.11比1.14±0.13），联合治疗后显著逆转CD4＋/CD8＋比值降低（1.41±0.10比1.14±0.13，P＝0.002）。结论免疫作用在TNBC治疗
Objective To study the immune inhibitory effect of chemotherapy on the treatment effect of three negative breast cancer （TNBC）. Methods TNBC tumor xenograft model in nude mice was established with MDAMB -231 - HM cells. 24 BABL/c nude mice with TNBC xenograft were randomly divided into tumor bearing group, chemotherapy group, and combination group. Tumor bearing group was the control group, 5 mg/kg paclitaxel were given by peritoneal injection twice a week in both chemotherapy group and combination group, 0. 2 mg/kg thymopeptides were given at the same time in combination group. After three weeks, the weight of the tumor tissue was detected and the activity of spleen cells was determined. The interleukin （IL） -2, tumor necrosis factor （TNF） -α, IL - 10 and IL -6 in the culture medium were determined by enzyme linked immunosorbent assay （ ELISA ）. Flow cytometry was used to detect CD4＋/CD8＋ in blood. Results （ 1 ） Compared to the tumor bearing group [ （ 3.12 ± 0. 32 ） g I, the tumor weight in chemotherapy group [ （1.32 ± 0. 67 ） g] was significantly decreased, the tumor weight in combination group [ （0.80 ±0.37） g] was significantly lower than in chemotherapy group. （2） As com-pared with the tumor bearing group, the levels of IL -2, IL - 10 and IL -6 in chemotherapy group were significantly decreased, the level of TNF -α was lower than the tumor bearing group but the difference is not significant. The value of IL-2 after 48 h were （13.39 ± 1.21 ） ng/L in the chemotherapy group vs. （16.65 ±1.28） ng/L in the tumor bearing group （P=0.030）, the value of IL -10 after 36 h were （223.03± 32. 24） ng/L in the chemotherapy group vs. （267.98 ± 42. 12） ng/L in the tumor bearing group （P =0. 041 ） , the value of IL -6 after 36 h were （39. 03 ± 10. 24） ng/L in the chemotherapy group vs. （47.98 ± 12. 12） ng/L in the tumor bearing group （ P = 0. 025 ） , the value of TNF -α after 36 h were （26. 94 ± 2. 94） ng/L in the chemotherapy group vs
出处
《中华实验外科杂志》
CSCD
北大核心
2017年第4期568-571,共4页
Chinese Journal of Experimental Surgery
关键词
免疫抑制
三阴性乳腺癌
化疗
Immunosuppression
Triple negative breast cancer
Chemotherapy
